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Summary
Evidence-based medicine has emerged as a valuable tool to guide clinical decision-making, by
summarizing the best possible evidence for both diagnostic and treatment strategies. Imaging
plays a critical role in the evaluation and treatment of patients with acute ischemic stroke,
especially those who are being considered for thrombolytic or endovascular therapy. Time from
stroke-symptom onset to treatment is a strong predictor of long-term functional outcome after
stroke. Therefore, imaging and treatment decisions must occur rapidly in this setting, while
minimizing unnecessary delays in treatment. The aim of this review was to summarize the best
available evidence for the diagnostic and therapeutic management of patients with acute ischemic
stroke.
In this era of health care reform and cost containment, major concerns have been raised
regarding inappropriate medical expenditures and the lack of data to support the necessity of
such high levels of health care spending. It is becoming ever more difficult to justify
diagnostic imaging and other medical procedures with anecdotal evidence, expert opinion,
or experience. Instead, great emphasis has been placed on the necessity for evidence-based
practice to guide clinical decision-making, especially in light of limited financial resources
and increased public awareness of imaging-related safety concerns, including risks from
radiation and contrast administration.
Evidence-based practice is defined as “integration of the best research evidence with clinical
expertise and patient values.” This necessitates the balance of scientific evidence, clinical
expertise, and judgment. When strong evidence is available and integrated in a methodical
fashion, practice guidelines can emerge, eventually shaping new standards of care. However,
when strong evidence is not available, clinical expertise and judgment play a major role in
medical decision-making.
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The aim of this review is to summarize the best available evidence for the diagnostic and
therapeutic management of patients with acute ischemic stroke. The first part of this review
synthesizes the most current evidence on the appropriate indications and modalities to
consider in the diagnostic work-up of patients with acute stroke. The second part examines
the efficacy of medical and mechanical interventions in acute stroke. Summary statements
along with strength of evidence are provided for each section as a quick reference. Table 1
describes the classification scheme used to determine the strength of evidence in the
literature.
Evidence-Based Imaging in Acute Ischemic Stroke
Because acute ischemic stroke and intracranial hemorrhage may have similar clinical
presentations, the primary imaging goal is to differentiate these 2 entities. Because
thrombolysis and endovascular therapy are associated with an increased risk of hemorrhage,
an additional imaging goal includes confirming the diagnosis while excluding stroke mimics
so that patients are not treated unnecessarily. Finally, for patients who do not meet the
criteria for IV thrombolysis but who arrive at the hospital relatively early after stroke onset,
emerging imaging goals also include identifying brain tissue that is still viable and
identifying the location of vascular occlusion when endovascular therapy is considered.
Imaging Evidence to Assess Intracranial Hemorrhage
CT—Although it is accepted that CT is sensitive in detecting acute ICH, surprisingly few
studies have been conducted to support this belief.1 One of the original studies on a first-
generation scanner in the 1970s identified 66 hemorrhages with CT, but the data lacked
postmortem confirmation. Subsequently, in a postmortem series of 79 patients, in 4 of 17
patients, CT missed ICHs—all of which were located in the brain stem.2 While there is little
doubt that the third-generation scanners are far superior today, the precise accuracy of CT
for the detection of ICH is unknown.
MR Imaging—MR imaging was reported to detect ICH within 6 hours and as early as 23
minutes from symptom onset.3,4 One study evaluated 62 patients with ICH within 6 hours of
onset and 62 controls, with 3 experienced readers using CT as the reference standard.5 The
readers, blinded to clinical and CT results, identified all acute hemorrhages on MR imaging,
yielding 100% sensitivity and specificity. A subsequent study comparing CT and MR
imaging for detection of hemorrhagic stroke within 6 hours of onset, using the discharge
diagnosis as the reference standard, found 86% sensitivity and 100% specificity for both CT
and MR imaging. Of 29 acute hemorrhages on CT, 25 were identified on MR imaging (in 3
of 4 cases, blood was misclassified as chronic instead of acute).6 Similarly, 4 cases of ICH
identified on MR imaging were not seen on CT (all were ischemic infarcts with hemorrhagic
transformation). Therefore, it appears that rare cases of early intracranial hemorrhage may
be missed on either CT or MR imaging. However, susceptibility-weighted sequences have
improved sensitivity in the detection of cerebral microbleeds that are not otherwise detected
on CT. Thus far, studies suggest that neither the presence nor number of microbleeds is
associated with an increased risk of hemorrhagic transformation in either tPA-treated or
untreated patients.7-9
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Summary of Evidence—In the evaluation of patients with acute stroke for IV
thrombolysis, CT has become the technique of choice for exclusion of ICH, based on
randomized controlled trials (strong evidence). Recent studies indicate that the accuracy of
MR imaging in detecting ICH is likely equivalent to that of CT even in the hyperacute
setting (within 6 hours of ictus) and is even more accurate for detection of chronic cerebral
microbleeds (moderate evidence).
Imaging Evidence to Assess Ischemia and Exclude Stroke Mimics
CT—The diagnosis of acute stroke is primarily based on the clinical history and physical
examination. At times, patients may present with strokelike symptoms due to nonstroke
etiologies. Stroke mimics may account for up to 19% of patients initially diagnosed with
stroke and up to 14% of patients treated with IV tPA.10,11 An additional goal of imaging is
to confirm diagnosis and to evaluate the extent of ischemic changes. Large ischemic strokes
may demonstrate early signs of ischemia on CT, including loss of gray-white differentiation,
hyperattenuated clot in the proximal MCA, sulcal effacement, and local mass effect. Such
signs were found in 31% and 81% of patients within 3 and 5 hours after symptom onset,
respectively.12,13 Early CT signs involving more than one-third of the MCA distribution
have been associated with large strokes, increased risk of hemorrhagic transformation, and
poor outcome.14-16 The Alberta Stroke Program Early CT Score (ASPECTS), a 10-point
scoring system to detect early ischemic changes on NCCT, was developed as a tool that
would be more reliable than the MCA rule.17 While ASPECTS was found to have superior
interobserver agreement, it only modestly improved accuracy for predicting functional
outcome and performed the same as the MCA rule for predicting symptomatic
hemorrhage.17,18
MR Imaging—DWI is more sensitive for detecting ischemic changes within minutes of
stroke onset and ischemic lesions as small as 4 mm in diameter compared with CT.19-21 As
time from symptom onset increased, the sensitivity of DWI for the diagnosis of ischemic
stroke also increased 73%, 81%, and 92% for <3 hours, 3–12 hours, and >12 hours,
respectively, whereas CT had only 12%, 20%, and 16% sensitivity at these respective time
intervals. The sensitivity for MR imaging to detect ischemia within 6 hours of onset is 81%–
91%; therefore, the absence of a DWI lesion does not completely exclude ischemic stroke.
DWI may be falsely negative in very early stroke and in patients with small subcortical or
vertebrobasilar infarctions or in patients with low stroke severity (NIHSS score < 4).21-24
Therefore, stroke timing, location, size, and perfusion status contribute to the visualization
of a DWI lesion.
Summary of Evidence—DWI is superior to CT for identifying acute ischemic stroke
within the first 12 hours of symptom onset (strong evidence). However, MR imaging does
not necessarily have a greater influence than CT on decision-making or clinical outcomes in
the acute setting, given its limited availability and the need for patient screening. Early CT
signs of ischemia involving more than one-third of the MCA distribution have been
associated with large strokes, increased risk of hemorrhagic transformation, and poor
outcome (strong evidence).
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Imaging Evidence to Determine Brain Tissue Viability
MR Imaging—An emerging goal of acute stroke imaging is to identify patients who may
benefit from treatment outside the current therapeutic window for IV thrombolysis. Thus,
identifying tissue that may be rescued with therapy (ie, the ischemic penumbra) has been a
major focus of clinical research. Using multimodal MR imaging, DWI is postulated to
delineate irreversibly injured tissue (infarct core), and PWI is postulated to delineate
critically hypoperfused tissue that will evolve into infarction if not reperfused in a timely
manner (ischemic penumbra). When DWI and PWI are superimposed, the nonoverlapping
“mismatched” region has been proposed to represent the penumbra.25,26 Consistent with the
idea of an evolving ischemic core, the DWI lesion may grow into a final infarct
approximating the early PWI abnormality.27 The DWI-PWI mismatch has been rapidly
translated into clinical trials under 3 categories of study design: 1) to select patients for
enrollment in the therapeutic trial, 2) to validate DPM as a biomarker of the penumbra, and
3) both (Table 2).
Within the first category, the Desmoteplase in Acute Ischemic Stroke trial (DIAS),28 the
Dose Escalation for Ischemic Stroke trial (DEDAS),29 and the DIAS-II30 have been
completed. These trials examined a novel thrombolytic agent, desmoteplase, compared with
placebo in patients demonstrating DPM between 3 and 9 hours after stroke onset. While the
initial phase-2 studies, DIAS and DEDAS, demonstrated safety and early signs of efficacy
for desmoteplase, the phase-3 study, DIAS-II, showed unexpectedly high mortality and no
overall clinical benefit. Unfortunately, these negative results did not permit an analysis of
which component of the study failed—the therapeutic agent or the DPM criteria.
Within the second category, the Diffusion and Perfusion Imaging Evaluation for
Understanding Stroke Evolution (DEFUSE) trial aimed to validate DPM by comparing
clinical outcomes in patients with DPM and reperfusion with outcomes in patients without
DPM and reperfusion; patients in both groups were treated with tPA between 3 and 6 hours
of stroke onset.31 Of 74 patients enrolled, 75% had DPM and 25% did not. In patients with
DPM, reperfusion was associated with better clinical outcome than no reperfusion.
However, due to the small number of patients without DPM (n = 11), the converse that
nonmismatch patients did not improve with reperfusion could not be proved. The high ratio
of mismatch to nonmismatch patients made it clear that the definition for DPM was too
liberal, resulting in a relatively unselected group of patients with stroke.
On the basis of the DEFUSE results, the DPM definition was refined for the DEFUSE-2
study.32,33 However, a subset of patients with DPM with “target mismatch” was selected,
which excluded patients with a “malignant profile” (large baseline DWI and PWI lesions)
because DEFUSE indicated that these patients have worse outcomes. Thus far, selection of
patients with the “target mismatch” definition demonstrated improved clinical outcome and
reduced infarct growth compared with the nontarget mismatch group.
Studies giving information about both the utility of the imaging biomarker and the efficacy
of treatment include the Echo-Planar Imaging Thrombolytic Evaluation Trial (EPITHET)34
and MR and Recanalization of Stroke Clots Using Embolectomy (MR-RESCUE).35 In
EPITHET, patients with stroke after 3 hours from symptom onset were serially imaged at 3
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time points: 1) before administration of tPA versus placebo, 2) at 3–5 days, and 3) at 90 days
after treatment. With its similarity to the DEFUSE protocol, most (86%) of enrolled patients
were categorized as having DPM, making conclusions regarding nonmismatch patients
difficult. The primary end point showed no difference in geometric mean infarct growth
between the tPA and placebo groups. MR-RESCUE,35 an ongoing study, aims to test both a
similar DPM protocol in combination with treatment by using the Merci retriever
(Concentric Medical, Mountain View, California) versus placebo up to 8 hours after stroke
onset.
Taking advantage of the endogenous susceptibility of deoxyhemoglobin on T2⋆-weighted
images is an active investigation into imaging oxygen metabolism by using MR imaging
(eg, MR-oxygen metabolic index),36-38 a parameter similar to PET-derived cerebral
metabolic rate of oxygen. If these physiologic measures of oxygen metabolism accurately
delineate the ischemic penumbra, they may yield ischemic thresholds that are time-
invariant,38 unlike diffusion and perfusion thresholds, which vary with elapsed time between
stroke onset and imaging.19,39 These relatively new imaging approaches will require
validation in well-designed trials.
CT—Similar to PWI, CTP is capable of providing maps of tissue perfusion. In a prospective
multicenter study, patients with acute stroke were imaged < 12 hours from stroke onset with
CT and MR imaging.40 The CTP parameter most accurately reflecting the ischemic core
(compared with DWI) was absolute CBV < 2 mL/100 g, while the parameter most
accurately reflecting the penumbra was a relative mean transit time of > 145% of the
contralateral hemisphere. However, in more recent studies, relative CBF was found to be
more predictive of the ischemic core and final infarct volume than absolute CBV.41-43
Recently, CTP mismatch with PWI used for both core (CBF) and penumbra (MTT, CBV) in
combination with intracranial vessel occlusion on CTA was used to select patients for entry
into a randomized controlled trial of IV tenecteplase versus IV tPA administered within 6
hours of stroke onset.44 This trial was positive for its co-primary end points, improvement in
the NIHSS score and percentage reperfusion at 24 hours. However, it is currently unknown
whether tenecteplase is superior to tPA in unselected patients because treatment without
CTA and CTP screening would save time and perhaps broaden the applicability of
tenecteplase.
Summary of Evidence—Determination of tissue viability by using advanced imaging
has the potential to individualize therapy and extend the therapeutic time window for some
patients with acute stroke. Several imaging modalities, including MR imaging, CT,and PET,
have been examined in this role. Operational hurdles have limited the use of some of these
modalities in the acute stroke setting (eg, PET), while others such as MR imaging have been
studied in large clinical trials. Randomized controlled trials have not demonstrated a benefit
of thrombolytic treatment in patients who are selected by using MR imaging–based criteria
such as DPM (moderate evidence); however, studies are ongoing. Clinical trials with
positive results will be needed before the use of penumbral imaging techniques in routine
clinical decision-making.
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Imaging Evidence to Determine the Location of Vascular Occlusion
CTA—An advantage of CTA is that it can be performed immediately after the prerequisite
NCCT in patients with stroke. In several small case series, the sensitivity and specificity of
CTA for trunk occlusions of the circle of Willis were 83%–100% and 99%– 100%,
respectively, compared with DSA.45-48 A study with 2 blinded observers comparing CTA
with DSA measured 475 short segments of intracranial arteries in 41 patients.47 For
detection of ≥50% stenosis, CTA had 97.1% sensitivity and 99.5% specificity. A similar
study of 672 vessel segments in 28 patients found excellent sensitivity and specificity for
intracranial stenosis of 98% and 98%, respectively, with 100% sensitivity and 100%
specificity for intracranial occlusion.48 This study also compared time-of-flight MRA with
CTA and found CTA to have significantly higher sensitivity and positive predictive value
compared with MRA (see below).
MRA—While MRA appears to be a useful tool for measuring stenosis in large extracranial
vessels, its sensitivity decreases for smaller caliber intracranial vessels. For time-of-flight,
complete or partial signal voids in regions of high and/or turbulent flow may occur, leading
to an overestimation of the extent of stenosis. Therefore, cautious interpretation of the lumen
caliber is warranted. In a study of intracranial disease comparing CTA and MRA with DSA
in 28 patients (in 672 vessel segments), time-of-flight MRA had a sensitivity of 70% and
81% and a specificity of 99% and 98% for intracranial stenosis and intracranial occlusion,
respectively.48 The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis
(SONIA) trial was a prospective multicenter study comparing the diagnostic accuracy of
transcranial Doppler and MRA with DSA.49 The SONIA study found that both transcranial
Doppler and MRA have high negative predictive values (86% and 91%, respectively) but
low positive predictive values (36% and 59%, respectively). Sensitivity and specificity could
not be obtained in this study because not every patient underwent DSA.49
Summary of Evidence—CTA and MRA have high diagnostic accuracy for detecting
large-vessel occlusion compared with DSA (strong evidence). However, evidence
supporting these imaging modalities in acute stroke management is lacking (limited
evidence). Prospective studies examining the accuracy of acute non-invasive vascular
imaging and whether it alters clinical outcome after stroke are needed.
Evidence-Based Treatment in Acute Ischemic Stroke
IV Thrombolytic Therapy
The National Institute of Neurological Disorders and Stroke (NINDS) stroke study proved
the efficacy of the use of IV alteplase within 3 hours of stroke onset in patients with MCA
stroke and no hemorrhage on NCCT.50 At 3 months, patients treated with alteplase were at
least 30% more likely to have minimal or no disability compared with those treated with a
placebo. The benefit occurred despite higher rates of ICH in alteplase-treated patients
compared with controls (6.4% versus 0.6%). Treatment with IV alteplase within 3 hours of
stroke onset was endorsed early by the Special Writing Group of the Stroke Council,
American Heart Association.51
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A number of studies followed that failed to prove the efficacy of IV alteplase in the 3- to 6-
hour time window. More recently, a meta-analysis was undertaken evaluating data from
trials with negative results only in the 3- to 4.5-hour time window. The meta-analysis
showed the efficacy of treatment with IV alteplase from 3 to 4.5 hours after MCA stroke
onset in patients with no hemorrhage and no signs of significant early infarct on NCCT.52
Multiple registries have been established, and these results further support the safety and
efficacy of IV alteplase in the 4.5-hour window.53-55
In general, IV thrombolysis is regarded as less effective in recanalizing large occlusive clots,
such as those of the terminal ICA or M1 MCA.56-60 The presence of a hyperdense MCA
sign on CT, indicating complete vessel occlusion, bodes poorly for patients treated with IV
tPA,58,59 which yields recanalization rates of 30% for proximal MCA occlusion and 10% for
ICA occlusion.60 On the basis of a subgroup analysis of the NINDS stroke study, despite
low rates of recanalization with proximal occlusions, IV tPA improved outcome in large
strokes.61 Presumably, much of the benefit of IV treatment derives from recanalization of
smaller more distal branches.
Summary of Evidence—IV thrombolysis is the standard-of-care treatment for acute
ischemic stroke in the anterior circulation within 4.5 hours of symptom onset (strong
evidence). Larger more proximal clots (ICA, M1 MCA) exhibit lower recanalization rates
with IV thrombolytic treatment, and such patients tend to have worse prognosis (strong
evidence).
IA Thrombolytic Therapy
Based on preliminary experience with IA therapy, the Prolyse in Acute Cerebral
Thromboembolism (PROACT) II trial was implemented to determine the clinical efficacy
and safety of intra-arterial r-proUK in patients with acute stroke.62 Only patients with MCA
infarct of <6 hours from onset and no evidence of hemorrhage or early signs of major infarct
on CT were included. Angiographic inclusion criteria were either complete occlusion (TIMI
0) or contrast penetration with minimal perfusion (TIMI 1) of either an M1 or M2 division
of the MCA. Following angiography, 180 patients met the criteria. These patients were
randomized in a 2:1 ratio to receive IA r-proUK plus heparin or heparin only. The results
indicated benefit for the treated group with 40% of r-proUK patients compared with 25% of
control patients achieving the primary outcome measure of a modified Rankin Scale score of
0–2, with similar mortality rates. Improved outcome in the treated group was noted despite
increased frequency of early symptomatic hemorrhage (within 24 hours, 10% versus 2%).
The recanalization rate was 66% for the r-proUK group and 18% for the control group (P < .
001). Treated and control patients with less severe strokes (NIHSS score ≤ 10) did equally
well. Patients with more severe strokes (NIHSS score > 10) were twice as likely as controls
to achieve the desired outcome measure. Considering the limitations of this study, many
investigators suspect that the demonstrated PROACT II benefit represents a lower limit for
IA treatment efficacy.
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Combined IV and IA Thrombolysis
Recognizing the trade-offs between IV and IA thrombolytic therapy, researchers have
studied combined therapy consisting of IV treatment followed by IA treatment.63 The
Interventional Management of Stroke (IMS) II trial compared combined IV/IA thrombolysis
with historical controls of IV thrombolytics alone and placebo from the NINDS stroke
study.64 Eighty-one patients who could be treated with IV alteplase within 3 hours from
symptom onset were enrolled. IV treatment consisted of two-thirds the usual alteplase dose
administered as a 15% bolus during 1 minute followed by the remainder for 30 minutes.
Once IV treatment had been initiated, the patient was transferred to the angiography suite. If
an IA treatment-amenable clot was identified, the remaining one-third of the alteplase dose
was administered in the clot. If no IA-amenable clot was identified, the remaining one-third
of the alteplase dose was administered IV. Of 81 patients, 55 under-went combined
treatment with the remainder receiving IV treatment alone. The combined IV/IA-treated
patients exhibited a better outcome than the NINDS alteplase-treated subjects by the Barthel
Index but not by other outcome measures. The patients with combined treatment had
significantly better outcome at 3 months than NINDS patients with placebo on all outcome
measures (odds ratio > 2). The 3-month mortality for IMS patients with combined treatment
(16%) trended lower than NINDS placebo- (24%) and alteplase-treated subjects (21%). The
difference was not statistically significant. A subsequent trial, IMS III, compared combined
IV alteplase alone with combined IV/IA treatment including mechanical devices. In April
2012, an independent data safety monitoring board placed the trial on hold because the
interim analysis indicated a very low likelihood of improved outcome with combined
treatment.
A prospective registry (RECANALISE [REcanalisation using Combined intravenous
Alteplase and Neurointerventional ALgorithm for acute Ischemic StrokE] study) compared
recanalization rates, 24-hour improvement, and 3-month functional outcome between
patients in 2 time intervals who underwent different thrombolytic protocols.65 In the first
time period, patients within 3 hours of symptom onset were treated with IV alteplase
according to standard protocol. In the second time interval, patients were treated with a
combined technique similar to that in IMS II. Early neurologic recovery (defined as NIHSS
0 or 1 or a 4-point improvement) occurred in 60% of patients with combined treatment
compared with 39% of those with IV treatment (P = .07); and 3-month functional outcome
(mRS 0–2) occurred in 57% of those with combined treatment compared with 44% of those
with IV treatment (P = .35). The 90-day mortality and symptomatic intracranial hemorrhage
rates were not appreciably different. The most pronounced difference observed was in the
recanalization rate: 87% in patients with combined treatment and 52% of those with IV
treatment (P = .0002).
Mechanical Endovascular Intervention
Mechanical clot removal has not been evaluated in a randomized controlled fashion. The
Merci retriever (Concentric Medical) and the Penumbra aspiration system (Penumbra,
Alameda, California)66-69 were evaluated in prospective multicenter single-arm design
trials. A historical control from PROACT II was often used, and the patients were treated for
up to 8 hours. In the Multi MERCI trial,67 mechanical thrombectomy was used in large-
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vessel stroke, in both anterior and posterior circulations, within 8 hours of onset. Patients
with persistent large-vessel occlusion after IV alteplase were also included. Successful
recanalization was reported in 57.3% (75 of 131) and a higher rate of 69.5% (91 of 131)
after adjunctive therapy consisting of IA alteplase. The study also showed improved efficacy
in recanalization with the new-generation devices. Significant complications were defined as
those procedural complications resulting in an NIHSS decline of ≥4 or death or groin
complication necessitating surgery and/or blood transfusion. Such clinically significant
complications were observed in 9 patients (5.5%). Symptomatic ICH occurred in 16 patients
(9.8%).
In the Penumbra Pivotal trial, patients with treatable large-vessel stroke <8 hours from onset
were enrolled.66 This study observed high recanalization rates (TIMI 2 or 3) of 81.6%.
However, 12.8% of patients (18 of 125) endured procedural complications with 2.4% (3
patients) considered serious, resulting in a significant negative impact on the patient.
Two stent retrievers have been developed and compared with the Merci system (Solitaire FR
Revascularization Device; Covidien, Irvine, California; and Trevo Pro Retrieval System;
Stryker, Kalamazoo, Michigan). Patients treated with both retriever systems showed
markedly improved rates of recanalization and reasonable safety.70,71 As with the MERCI
and Penumbra studies, safety was demonstrated along with high rates of recanalization;
however, the clinical efficacy data are lacking. Both devices received FDA approval in
2012.
Summary of Evidence—IA thrombolysis may be used at a qualified stroke center to treat
patients with major stroke due to MCA occlusion in <6 hours who cannot receive IV
alteplase (strong evidence). The FDA has approved several mechanical devices for
intracranial clot removal in appropriately selected patients up to 8 hours from symptom
onset (strong evidence). Although considered appropriate for emergency stroke treatment,
the effect on outcomes has not been established.
Conclusions
CT has been used as the first-line imaging to assess ICH in patients with acute stroke.
Although MR imaging has equivalent accuracy in detecting ICH and is superior to CT
within the first 24 hours for detection of ischemia, it should be used only if treatment is not
delayed because the time from stroke-symptom onset to treatment is a strong predictor of
long-term functional outcome. Non-invasive vascular imaging (CTA, MRA) to assess the
location and extent of clot and perfusion imaging to assess viable tissue are promising
imaging techniques that may be used to select patients for novel thrombolytic agents and
interventional devices. Therefore, further studies assessing their accuracy and impact on
clinical outcomes are greatly needed. Regarding treatment of acute ischemic stroke, strong
evidence exists proving the efficacy of IV and IA thrombolysis up to 4.5 and 6 hours,
respectively, from stroke symptom onset. Mechanical thrombectomy has been approved in
selected patients up to 8 hours.
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Abbreviations
DPM diffusion-perfusion mismatch
IA intra-arterial
ICH intracranial hemorrhage
r-proUK recombinant prourokinase
TIMI Thrombolysis in Myocardial Infarction
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Table 1
Classification scheme for the strength of evidence
Strength of Evidence Criteria Used
Strong Studies with broad generalizability to most patients suspected of having the disease; include prospective, blinded
comparison of a diagnostic test with a well-defined final diagnosis in an unbiased sample when assessing diagnostic
accuracy or blinded randomized control trials when assessing therapeutic impact or patient outcomes; also included
are well-designed meta-analyses
Moderate Prospective or retrospective studies with narrower spectrum of generalizability, with only a few flaws that are well-
described so that their impact can be assessed but still include a blinded study of diagnostic accuracy on an unbiased
sample (well-designed cohort or case-control studies) and randomized trials for therapeutic effects or patient
outcomes
Limited Diagnostic accuracy studies with several flaws in research methods, small sample sizes, incomplete reporting, or
nonrandomized comparisons for therapeutic impact or patient outcomes
Insufficient Studies with multiple flaws in research methods, case series, descriptive studies, or expert opinions without
substantiating data
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Table 2
Clinical studies testing penumbral imaging markers
Study Name Validation of the Imaging
Biomarker
Testing a Treatment on the Basis of Selection of
Patients with an Imaging Biomarker
DIAS,28 DEDAS,29 DIAS-2,30 IV tenecteplase,44,a No Yes
DEFUSE,31 DEFUSE-2,32,33 Yes No
EPITHET,34 MR-RESCUE35 Yes Yes
a
This trial required intracranial vessel occlusion on CTA and CTP mismatch for randomization.
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